A Decisional Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients Naive to Iron Chelation Therapy. A Comparative Randomized Prospective Study

Trial Profile

A Decisional Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients Naive to Iron Chelation Therapy. A Comparative Randomized Prospective Study

Completed
Phase of Trial: Phase II/III

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Deferiprone (Primary)
  • Indications Beta-thalassaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jul 2017 New trial record
    • 25 Jun 2017 Primary endpoint (determine the time and number of transfusion units as well as amount of infused iron that will lead to appearance of LPI > 0.2 or TSAT>50 % , serum ferritin >/= 500 ng/ml in the studied thalassemic patients which warrant start of iron chelation) has been met according to results presented at the 22nd Congress of the European Haematology Association.
    • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top